With a heterogeneous population with regards to the FGFR3 mutation, low proliferation rates of FGFR3 mutants results in a situation in which ICI monotherapy results in at least 90% reduction in tumor burden on Day 25 relative to control (Figure 5A). The gene discussed is FGFR3; the disease is neoplasm.